Cannabis Law Report

OCTOBER 2, 2021

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. We are pioneering a new kind of pharmaceutical company that prioritizes public benefit and is committed to sustainability, accountability, and transparency.

Clinical Trials 52

Clinical Trials Research and Development Compliance Compliance 52

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. Team leadership : mentor European study teams in overall regulatory strategy and compliance to enable future patient access expeditiously.

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. A minimum of 5-7 years of legal experience in healthcare or pharmaceutical-related fields. Deputy General Counsel Executive Summary.

Therapy 40

Therapy Compliance Compliance Clinical Trials 40

Cannabis Law Report

JULY 24, 2019

Curaleaf CURLF, -7.27% is “illegally selling unapproved products containing cannabidiol (CBD) online with unsubstantiated claims that the products treat cancer, Alzheimer’s disease, opioid withdrawal, pain and pet anxiety, among other conditions or diseases,” the FDA wrote. Full report at. Full Letter. Source: [link]. 321(g)(1)(B).

CBD 51

CBD Tincture Pets Chronic Pain 51